PropertyValue
?:abstract
  • The outbreak of coronavirus disease 2019 (COVID-19) in December 2019 in China, has become a pandemic in March 2020 Repurposing old and relatively safe drugs becomes an advantageous option to obtain the urgently needed effective treatment Repurposing chloroquine, hydroxychloroquine, oseltamivir, lopinavir/ritonavir, and favipiravir, and the use of investigational drug remdesivir for treatment of COVID-19, are reviewed from the clinical pharmacology perspective, particularly its efficacy and safety Limited clinical studies of chloroquine, hydroxychloroquine, favipiravir, and remdesivir showed some efficacy in COVID-19 treatment with tolerable adverse effects Potential serious adverse effect of chloroquine and hydroxychloroquine is cardiac arrhythmia Oseltamivir has no documented activity against SARS-CoV-2, while lopinavir/ritonavir showed limited efficacy in COVID-19 Currently, there is no sufficient evidence to recommend any specific anti-COVID-19 treatment The decision to use these drugs during the COVID-19 pandemic must be based on careful consideration of the potential benefits and risks to the patient
is ?:annotates of
?:creator
?:journal
  • Medical_Journal_of_Indonesia
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • Antiviral treatment of COVID-19: a clinical pharmacology narrative review
?:type
?:who_covidence_id
  • #890725
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/j1xxnmly>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/j1xxnmly>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all